Fortress Biotech Receives Annual Equity Grant, Increasing Stake to 8.0% and Maintaining Voting Control

summarizeSummary

Fortress Biotech, Inc. received an annual equity grant of 278,385 common shares, increasing its beneficial ownership to 8.0% and maintaining voting control through Class A preferred stock.

check_boxKey Events

• Annual Equity Grant Received

  Fortress Biotech, Inc. received an annual equity grant of 278,385 shares of Mustang Bio common stock, valued at approximately $309,000. This grant is pursuant to a pre-existing Founders Agreement.

• Increased Beneficial Ownership

  The grant increases Fortress Biotech's beneficial ownership to 536,910 shares, representing 8.0% of Mustang Bio's outstanding common stock.

• Significant Dilution

  The equity grant represents approximately 3.81% dilution to existing common shareholders, a material impact for a company of this market capitalization.

• Maintained Voting Control

  Fortress Biotech continues to hold all outstanding Class A preferred stock, which provides a voting majority (1.1 times the voting power of common stock) over Mustang Bio.

auto_awesomeAnalysis

Fortress Biotech, Inc., the founder and a significant shareholder of Mustang Bio, Inc., received an annual equity grant of 278,385 common shares, valued at approximately $309,000 based on the current stock price. This grant, part of a pre-existing Founders Agreement, represents a substantial dilution of approximately 3.81% for existing common shareholders. While expected under the agreement, the magnitude of this annual dilution is notable for a micro-cap company. Fortress Biotech also maintains a voting majority through its ownership of all outstanding Class A preferred stock, which grants it 1.1 times the voting power of common stock, ensuring continued control over the company's strategic direction.